



## HIV Vaccine

Guest Editor:

### **Dr. Chitra Upadhyay**

Department of Medicine, Division  
of Infectious Diseases, Icahn  
School of Medicine at Mount  
Sinai, One Gustave L Levy Place,  
Box 1090, New York, NY 10029E,  
USA

Deadline for manuscript  
submissions:

**closed (28 February 2021)**

### **Message from the Guest Editor**

This Special Issue of *Vaccines* on the “HIV vaccine” aims to highlight the unprecedented challenges and the advances that have been made in HIV-1 vaccine field since the RV144 trial. The issue will include research articles, reviews, and short communications on topics including, but not limited to, novel approaches to elicit protective innate, humoral, and cellular responses; the induction of neutralizing and non-neutralizing antibodies and their roles in protection; epitope-based and antibody lineage-based HIV-1 vaccine approaches; and advances in vaccine vectors and adjuvants. The issue will also highlight the unique challenges associated with HIV-1 vaccine development including the high mutability, extreme glycosylation, and poor immunogenicity of HIV-1, the lack of a validated animal model that can fully recapitulate the infection and pathogenesis of HIV in humans, and the lack of definitive correlates of vaccine protection. Thus, this issue will showcase the incredible achievements made in the HIV-1 vaccine field in the last decade.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)